Business
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models
WALTHAM, Mass., January 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals XyntheticaTM offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery.
About this update from Revvity, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":784,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/36d5cdf9ed3c61a49a27a967eaf73629"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zi0r.WSl8Ao7sIe2hfy8zQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/36d5cdf9ed3c61a49a27a967eaf73629","width":784,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/TCVttZSUTJVFyxH0Nee6oA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE1Njg7aD02NDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/36d5cdf9ed3c61a49a27a967eaf73629","width":784,"height":320}},"lazy":false},{"type":"text","content":"Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering","length":124,"tagName":"p","attribs":{}},{"type":"text","content":"WALTHAM, Mass., January 09, 2026--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals XyntheticaTM offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery.","length":458,"tagName":"p"},{"type":"text","content":"Lilly TuneLab was established to make advanced AI/ML models, trained on decades of Lilly research data, available to the broader biotech community in exchange for data contributions that improve model performance through federated learning. The Signals Xynthetica platform operationalizes the delivery of the Lilly TuneLab models directly within the Signals platform, where experimental data is already captured, curated, and analyzed by thousands of discovery teams worldwide.","length":477,"tagName":"p"},{"type":"text","content":""Federated learning represents one of the most powerful paths forward for AI in drug discovery, but it requires the right platform to succeed," said Kevin Willoe, president of Revvity Signals Software. "By providing access to Lilly’s worldclass predictive models through the Signals Xynthetica platform, we are creating a practical, secure way for organizations of all size...